tirzepatide weight loss program telehealth Fridays | GLP-1 Tirzepatide | Weight Loss Medication
Description
The dual GIP/GLP-1 mechanism in tirzepatide produces more significant gastric emptying delays
Tirzepatide activates both GLP-1 and GIP receptors simultaneously, making it a dual agonist
Smooth process, good experience
Since the glucose-lowering effects of GIP have been shown to be impaired in patients with T2D, interest has focused on developing antidiabetic therapies based upon the actions of GLP-1 and GIP, the response to which remains intact
Because tirzepatide targets both GIP and GLP-1 pathways, it often yields greater weight loss than medications targeting GLP-1 alone
